The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Compliance for Peptide Therapy and BPC 157 Holt Law The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter peptides #fda #longevity #glp1 #precisionmedicine #compounding Katherine Erickson The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Considerations Regarding the 503B to 503A Compounding Model For Community Pharmacies Pharmacy Times